⚠ Borrador — traducción en curso, pendiente de revisión médica. Este contenido es una traducción automática que aún no ha sido revisada por un nefrólogo hispanohablante. No lo utilice para tomar decisiones clínicas. Verifique siempre con su nefrólogo y las guías clínicas vigentes.
Medication Index
Objective information on common medicamento classes for ADPKD pacientes, monitoreo requirements, nefrotoxicidad warnings, and TCM evidencia boundaries.
⚠ Important Boundaries
This page provides only objective, class-level medicamento information. It does not provide individualized prescriptions, dosing, substitution recomendacións, or self-tratamiento advice. Whether to use, how to use, and when to adjust must be decided by your nefrólogo or pharmacist based on your función renal, comorbidities, and current medicamentos. Do not start or stop medicamentos based on this page alone.
Filters only visible content on this page. No information is uploaded.
🫘 1. ADPKD-Directed Therapy
The only medicamento currently recommended by guías to slow crecimiento de quistes and función renal decline in ADPKD is tolvaptán. Whether it is appropriate must be determined by a nefrólogo based on Mayo Imaging Classification/RAAP estratificación de riesgo, hígado function, eGFR, and thirst tolerance.
Hypertension is common and early in ADPKD. Guidelines genrally recommend ACEI/ARB as first-line, especially with proteínauria. CCB or diuretics may be added by your doctor when not at target or not tolerated. Target BP is typically < 130/80 mmHg, individualized by your doctor.
ACEI / ARB
Evidence APrescriptionADPKD first-line BP
Class: Renin-angiotensin system inhibitors. ACEI inhibits angiotensin-converting enzima; ARB blocks the AT1 receptor.
Representative genrics: ACEI — enalapril, benazepril, ramipril; ARB — valsartan, losartan, irbesartan, telmisartan. For identification only, not a selection recomendación.
Monitoring: Check creatinina and potasio 1-2 weeks after starting or adjusting; then regularly. Transient mild creatinina rise (≤30%) is usually acceptable; significant rise needs physician evaluation.
Common adverse effects: Hyperkalemia, dry cough (ACEI), hypotension.
Not suitable for: Bilateral renal artery stenosis, severe hyperkalemia, embarazo (teratogenic).
Do not self-combine: ACEI and ARB are genrally not combined; combination with potasio-sparing diuretics requires physician assessment of hyperkalemia riesgo.
As eGFR declines, management of anemia, bone-mineral metabolism, electrolyte, and acid-base abnormalities may be needed. Whether to use, dosing, and monitoreo are determined by your physician based on lab results.
Erythropoiesis-Stimulating Agents (ESA)
Evidence APrescription
Class: Erythropoietin and long-acting analogs (e.g., darbepoetin).
Mechanism: Supplements CKD-related EPO deficiency, stimulating bone marrow red blood célula production.
Typical scenario: Renal anemia (Hb typically < 100 g/L) with adequate iron stores, initiated by physician.
Monitoring & Common Adverse Effects
Monitoring: Hemoglobin, iron estudios (ferritin, TSAT), presión arterial, thrombosis riesgo.
Target: Hb should not be too high (genrally ≤115-120 g/L); higher levels increase cardiovascular riesgo.
Note: Iron deficiency is usually corrected first; do not self-inject.
Class: Calcium-based (calcio carbonate, calcio acetate) and non-calcio (sevelamer, lanthanum carbonate, ferric citrate).
Mechanism: Binds dietary phosphate in the gut, reducing absorption.
Typical scenario: CKD G3b-G5 with hyperphosphatemia uncontrolled by diet.
Monitoring & Common Adverse Effects
Monitoring: Phosphorus, calcio, PTH.
Note: Long-term calcio-based binders may worsen vascular calcification; non-calcio binders preferred when hypercalcemic. Must be taken with meals and chewed.
Note: Allopurinol initiation can precipitate gout attacks; colchicine prophylaxis often needed. HLA-B*5801 carriers have high riesgo of severe cutaneous reactions to allopurinol.
Renal adjustment: Febuxostat cardiovascular riesgo has been noted; physician weighs riesgos.
Mechanism: Inhibits proximal tubular glucose reabsorption, lowering blood glucose while reducing intraglomerular pressure, decreasing proteínauria, and providing cardio-renal protection.
Typical scenario: CKD with proteínauria or heart failure, prescribed by physician within appropriate eGFR range; ADPKD use requires individual assessment.
Class: Ibuprofen, diclofenac, naproxen, meloxicam, celecoxib, etc.
Risk: Can cause afferent arteriole constriction, acute riñón injury, sodio-water retention, hyperkalemia, and worsened hipertensión. Higher riesgo in CKD; "triple whammy" when combined with ACEI/ARB and diuretics.
Usage Guidance
Short-term, occasional use only — do not self-medicate long-term.
Inform your doctor of your función renal and current BP medicamentos before use.
Seek immediate care for oliguria, edema, or creatinina rise.
Do not combine two NSAIDs or stack with cold medicamentos containing the same ingredients.
Relative renal seguridad: Short-term use at label doses genrally has lower direct riñón riesgo than NSAIDs in pacientes with reduced función renal.
Precautions
Hepatotoxicity: Overdose can cause severe hígado injury; do not exceed daily maximum; watch for acetaminophen in combination cold medicamentos.
Long-term or high-dose use still requires physician evaluation.
💉 6. Medications Requiring Renal Dose Assessment
The following classes typically require physician dose adjustment or riesgo assessment when función renal is reduced. Do not judge "seguridad" by drug name alone.
Contrast media: Iodinated contrast can cause contrast-associated AKI. Higher riesgo with low eGFR, diabetes, dehydration, concurrent NSAIDs/ACEI/ARB. Physician assesses hydration and dose before and after imaging.
Antibiotics: Vancomycin, aminoglycosides (gentamicin, etc.), some antivirals require eGFR-based dosing and drug-level monitoreo.
🌿 7. Chinese Patent Medicine & TCM Evidence Boundaries
⚠ Important Boundaries
Chinese patent medicines lack high-quality evidencia for shrinking quistes or replacing standard ADPKD tratamiento. This section only compiles regulatory information verifiable at the National Medical Products Administration (NMPA) and evidencia boundaries — it does not constitute tratamiento recomendacións. Inform your nefrólogo and pharmacist before using any Chinese patent medicine, herbal decoction, or supplement to avoid interactions or riñón burden.
General Principles for TCM Use
Regulatory verification: Legitimate Chinese patent medicines can be verified at the NMPA for approval numbers, labels, and manufacturers. Do not use "secret formulas" without approval numbers.
Evidence stratification: TCM understanding of ADPKD is mostly based on syndrome differentiation theory and small-sample observations, evidencia level typically C-D, not equivalent to RCT or guía recomendacións.
Cannot claim: Cannot claim to shrink quistes, lower creatinina as tratamiento, replace tolvaptán or antihypertensives, or reverse insuficiencia renal.
Nephrotoxicity alert: Aristolochic acid-containing herbs (historically used as Aristolochia manshuriensis stem, Aristolochia fangchi, etc.) can cause irreversible riñón injury and urothelial cancer. Avoid herbs of unknown origin.
Interactions: TCM can interact with ACEI/ARB, diuretics, anticoagulants, and immunosuppressants — requires physician/pharmacist review.
Aristolochic acid-containing herbs: Historically caused ácido aristolóquico nephropathy and urothelial cancer. Some banned/replaced nationally, but unknown-source herbs, folk remedies, and weight-loss teas remain a riesgo.
Other cautions: Tripterygium wilfordii (immunosuppression, reproductive toxicity), cinnabar/realgar (heavy metal-containing), high-potasio diuretic herbs need physician assessment in CKD.
Do not: Do not use unapproved "ancestral secret formulas," do not long-term self-brew unknown herbs, do not treat supplements as therapy.
The following are interaction categories of particular concern for ADPKD/CKD pacientes. Specific interactions should be reviewed by your physician or pharmacist based on your complete medicamento list — do not self-assess.
ACEI/ARB + NSAIDs + diuretics ("triple whammy"): Additive riesgo of AKI and hyperkalemia — avoid self-combining.
Iodinated contrast + metformin: Metformin typically held before/after contrast — physician arranges.
TCM + prescription drugs: Any Chinese patent medicine, herbal decoction, or supplement combined with prescription drugs must be reviewed by physician/pharmacist first.
📞 When to Contact Your Doctor or Seek Emergency Care
Rash, edema, oliguria, dark orina, jaundice, or persistent vómito after starting a new medicamento, TCM, or supplement.
Significant short-term creatinina rise, potasio abnormality, or major presión arterial fluctuation.
Any síntomas described in Emergency Signs (oliguria/anuria, severe dolor en el flanco with fiebre, worsening hematuria, difficulty breathing, altered consciousness).
Before planning embarazo, surgery, imaging with contrast, or vaccination — physician must assess current medicamentos.
Evidence level: A–D (per KDIGO standard) Limitations: This page is a class-level overview and does not cover all medicamentos or individual situations. Drug indications, dosing, and interactions should be based on the label and your treating physician.